Table 1 Comparison of clinical characteristics of patients between DEB-TACE and cTACE
Items | DEB-TACE (N = 80) | cTACE (N = 100) | p-value |
|---|---|---|---|
Age (years), mean ± SD | 50.8 ± 7.4 | 51.5 ± 6.8 | 0.510 |
Gender, no. (%) | |||
Male | 63 (78.6%) | 78 (78%) | 0.903 |
Female | 17 (21.4%) | 22 (22%) | |
Etiology, no. (%) | |||
HBV | 53 (66.3%) | 70 (70%) | 0.897 |
HCV | 10 (12.5%) | 12 (12%) | |
Alcohol | 8 (10%) | 10 (10%) | |
Others | 9 (11.2%) | 8 (8%) | |
Number of tumors, no. (%) | |||
1–3 | 65 (81.2%) | 83 (83%) | 0.760 |
≥ 4 | 15 (18.8%) | 17 (17%) | |
Largest tumor diameter (cm), mean ± SD | 8.69 ± 0.44 | 8.35 ± 0.45 | 0.605 |
Portal vein invasion, no. (%) | 13 (16.25%) | 18 (18%) | 0.757 |
Lymphadenectasis, no. (%) | 15 (18.8%) | 20 (20%) | 0.833 |
Distant metastasis, no. (%) | 8 (10%) | 12 (12%) | 0.671 |
Liver involvement, no. (%) | |||
≤ 50% | 7 (8.7%) | 15 (15%) | 0.419 |
50–70% | 60 (75%) | 68 (68%) | |
≥ 70% | 13 (16.3%) | 17 (17%) | |
ECOG score, no. (%) | |||
0–1 | 73 (91.3%) | 85 (85%) | 0.203 |
2 | 7 (8.7%) | 15 (15%) | |
BCLC stage, no. (%) | |||
A | 23 (28.7%) | 27 (27%) | 0.684 |
B | 45 (56.3%) | 53 (53%) | |
C | 12 (15%) | 20 (20%) | |
Child-Pugh stage, no. (%) | |||
A | 70 (87.5%) | 83 (83%) | 0.401 |
B | 10 (12.5%) | 17 (17%) | |
Cycles of DEB-TACE, no. (%) | |||
1–2 | 54 (67.5%) | 76 (76%) | 0.816 |
≥ 3 | 26 (32.5%) | 34 (34%) | |
Conversion rate, no. (%) | |||
Yes | 15 (18.8%) | 8 (8%) | 0.032* |
No | 65 (81.2%) | 92 (92%) | |